Dorzagliatin monotherapy in Chinese patients with type 2 diabetes a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.-学术期刊.pdf

Articles Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study Dalong Zhu, Shenglian Gan, Yu Liu, Jianhua Ma, Xiaolin Dong, Weihong Song, Jiao’e Zeng, Guixia Wang, Wenjuan Zhao, Qiu Zhang, Yukun Li, Hui Fang, Xiaofeng Lv, Yongquan Shi, Haoming Tian, Linong Ji, Xin Gao, Lihui Zhang, Yuqian Bao, Minxiang Lei, Ling Li, Longyi Zeng, Xiaoying Li, Xinghua Hou, Yu Zhao, Tianxin Hu, Xiaoyun Ge, Guiyu Zhao, Yongguo Li, Yi Zhang, Li Chen Summary Background Glucokinase acts as a glucose sensor in the pancreas and a glucose processor in the liver, and has a Lancet Diabetes Endocrinol 2018 central role in glucose homoeostasis. Dorzagliatin is a new, dual-acting, allosteric glucokinase activator that targets Published Online both pancreatic and hepatic glucokinases. Dorzagliatin has good pharmacokinetic and pharmacodynamic properties May 4, 2018 in humans, and provides effective 24-h glycaemic control and improves glucose sensitivity in patients with /10.1016/ S2213-8587(18)30105-0 type 2 diabetes. We aimed to assess the efficacy and safety of dorzagliatin monotherapy at different doses in Chinese See Online/Comment patients with type 2 diabetes.